The novel myokine irisin: clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women

Hye Sun Park, Hyun Chang Kim, Dongdong Zhang, Hyungseon Yeom, Sungkil Lim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: To clarify the association of circulating irisin with muscle, liver and bone, and to evaluate irisin as a biomarker for sarcopenia in postmenopausal women. Methods: Quadriceps cross-sectional area (QcCSA), bone mineral density (BMD), liver attenuation (measured in Hounsfield units (HU)) were assessed using quantitative computed tomography in 153 postmenopausal women, mean age of 72.20 ± 5.96 years. Muscle strength and physical performance were evaluated by handgrip test and short physical performance battery, respectively. Serum irisin was measured by an enzyme-linked immunosorbent assay kit. In addition, 147 young women were recruited as a reference group to define cut-off values for sarcopenia. Results: Circulating irisin was positively correlated with QcCSA/body weight (BW) and liver HU even after adjusting for multiple covariates, and the serum level was significantly lower in the sarcopenia group (QcCSA/BW<−2SD of the mean values for young women) than in the presarcopenia (−2SD≤QcCSA/BW<−1SD) or control groups (1SD≤QcCSA/BW<2SD). Logistic regression models showed that the relationship between circulating irisin and prevalence of sarcopenia remained significant after adjusting for confounding factors (per 1.0 ng/mL decrease of irisin, odds-ratio = 1.95, 95% confidence interval 1.33–2.87, p-value = 0.001). Conclusions: In postmenopausal women, serum irisin may be used as a biomarker for sarcopenia, and we showed the potential for the development of irisin-based early screening and staging tool for sarcopenia.

Original languageEnglish
Pages (from-to)341-348
Number of pages8
JournalEndocrine
Volume64
Issue number2
DOIs
Publication statusPublished - 2019 May 15

Fingerprint

Sarcopenia
Biomarkers
Body Weight
Liver
Logistic Models
Serum
Muscle Strength
Bone Density
Enzyme-Linked Immunosorbent Assay
Odds Ratio
Tomography
Confidence Intervals
Bone and Bones
Muscles
Control Groups

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Park, Hye Sun ; Kim, Hyun Chang ; Zhang, Dongdong ; Yeom, Hyungseon ; Lim, Sungkil. / The novel myokine irisin : clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women. In: Endocrine. 2019 ; Vol. 64, No. 2. pp. 341-348.
@article{7265b40090e54e0dbcdc0704aee077ad,
title = "The novel myokine irisin: clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women",
abstract = "Purpose: To clarify the association of circulating irisin with muscle, liver and bone, and to evaluate irisin as a biomarker for sarcopenia in postmenopausal women. Methods: Quadriceps cross-sectional area (QcCSA), bone mineral density (BMD), liver attenuation (measured in Hounsfield units (HU)) were assessed using quantitative computed tomography in 153 postmenopausal women, mean age of 72.20 ± 5.96 years. Muscle strength and physical performance were evaluated by handgrip test and short physical performance battery, respectively. Serum irisin was measured by an enzyme-linked immunosorbent assay kit. In addition, 147 young women were recruited as a reference group to define cut-off values for sarcopenia. Results: Circulating irisin was positively correlated with QcCSA/body weight (BW) and liver HU even after adjusting for multiple covariates, and the serum level was significantly lower in the sarcopenia group (QcCSA/BW<−2SD of the mean values for young women) than in the presarcopenia (−2SD≤QcCSA/BW<−1SD) or control groups (1SD≤QcCSA/BW<2SD). Logistic regression models showed that the relationship between circulating irisin and prevalence of sarcopenia remained significant after adjusting for confounding factors (per 1.0 ng/mL decrease of irisin, odds-ratio = 1.95, 95{\%} confidence interval 1.33–2.87, p-value = 0.001). Conclusions: In postmenopausal women, serum irisin may be used as a biomarker for sarcopenia, and we showed the potential for the development of irisin-based early screening and staging tool for sarcopenia.",
author = "Park, {Hye Sun} and Kim, {Hyun Chang} and Dongdong Zhang and Hyungseon Yeom and Sungkil Lim",
year = "2019",
month = "5",
day = "15",
doi = "10.1007/s12020-018-1814-y",
language = "English",
volume = "64",
pages = "341--348",
journal = "Endocrine",
issn = "0969-711X",
publisher = "Humana Press",
number = "2",

}

The novel myokine irisin : clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women. / Park, Hye Sun; Kim, Hyun Chang; Zhang, Dongdong; Yeom, Hyungseon; Lim, Sungkil.

In: Endocrine, Vol. 64, No. 2, 15.05.2019, p. 341-348.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The novel myokine irisin

T2 - clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women

AU - Park, Hye Sun

AU - Kim, Hyun Chang

AU - Zhang, Dongdong

AU - Yeom, Hyungseon

AU - Lim, Sungkil

PY - 2019/5/15

Y1 - 2019/5/15

N2 - Purpose: To clarify the association of circulating irisin with muscle, liver and bone, and to evaluate irisin as a biomarker for sarcopenia in postmenopausal women. Methods: Quadriceps cross-sectional area (QcCSA), bone mineral density (BMD), liver attenuation (measured in Hounsfield units (HU)) were assessed using quantitative computed tomography in 153 postmenopausal women, mean age of 72.20 ± 5.96 years. Muscle strength and physical performance were evaluated by handgrip test and short physical performance battery, respectively. Serum irisin was measured by an enzyme-linked immunosorbent assay kit. In addition, 147 young women were recruited as a reference group to define cut-off values for sarcopenia. Results: Circulating irisin was positively correlated with QcCSA/body weight (BW) and liver HU even after adjusting for multiple covariates, and the serum level was significantly lower in the sarcopenia group (QcCSA/BW<−2SD of the mean values for young women) than in the presarcopenia (−2SD≤QcCSA/BW<−1SD) or control groups (1SD≤QcCSA/BW<2SD). Logistic regression models showed that the relationship between circulating irisin and prevalence of sarcopenia remained significant after adjusting for confounding factors (per 1.0 ng/mL decrease of irisin, odds-ratio = 1.95, 95% confidence interval 1.33–2.87, p-value = 0.001). Conclusions: In postmenopausal women, serum irisin may be used as a biomarker for sarcopenia, and we showed the potential for the development of irisin-based early screening and staging tool for sarcopenia.

AB - Purpose: To clarify the association of circulating irisin with muscle, liver and bone, and to evaluate irisin as a biomarker for sarcopenia in postmenopausal women. Methods: Quadriceps cross-sectional area (QcCSA), bone mineral density (BMD), liver attenuation (measured in Hounsfield units (HU)) were assessed using quantitative computed tomography in 153 postmenopausal women, mean age of 72.20 ± 5.96 years. Muscle strength and physical performance were evaluated by handgrip test and short physical performance battery, respectively. Serum irisin was measured by an enzyme-linked immunosorbent assay kit. In addition, 147 young women were recruited as a reference group to define cut-off values for sarcopenia. Results: Circulating irisin was positively correlated with QcCSA/body weight (BW) and liver HU even after adjusting for multiple covariates, and the serum level was significantly lower in the sarcopenia group (QcCSA/BW<−2SD of the mean values for young women) than in the presarcopenia (−2SD≤QcCSA/BW<−1SD) or control groups (1SD≤QcCSA/BW<2SD). Logistic regression models showed that the relationship between circulating irisin and prevalence of sarcopenia remained significant after adjusting for confounding factors (per 1.0 ng/mL decrease of irisin, odds-ratio = 1.95, 95% confidence interval 1.33–2.87, p-value = 0.001). Conclusions: In postmenopausal women, serum irisin may be used as a biomarker for sarcopenia, and we showed the potential for the development of irisin-based early screening and staging tool for sarcopenia.

UR - http://www.scopus.com/inward/record.url?scp=85058941441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058941441&partnerID=8YFLogxK

U2 - 10.1007/s12020-018-1814-y

DO - 10.1007/s12020-018-1814-y

M3 - Article

C2 - 30570737

AN - SCOPUS:85058941441

VL - 64

SP - 341

EP - 348

JO - Endocrine

JF - Endocrine

SN - 0969-711X

IS - 2

ER -